Amplify YieldShares Oil Hedged MLP Income ETF (AMLX): Price and Financial Metrics ETF
AMLX Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market
| Current price | $1.78 | 52-week high | $30.50 |
| Prev. close | $1.88 | 52-week low | $1.76 |
| Day low | $1.76 | Volume | 2,479,100 |
| Day high | $1.91 | Avg. volume | 2,811,742 |
| 50-day MA | $7.43 | Dividend yield | N/A |
| 200-day MA | $15.06 |
AMLX Stock Price Chart Interactive Chart >
Amplify YieldShares Oil Hedged MLP Income ETF (AMLX) ETF Bio
The investment objective of the Amplify YieldShares Oil Hedged MLP Income ETF is to selects its components from the Oil Hedged MLP Index with the intention of outperforming the index. It also holds short positions in WTI crude oil futures to limit the fund’s correlation with oil prices.
AMLX ETF Info
| Issuer | |
| Expense Ratio | % |
| Asset Class | |
| Sector | MLP ETFs |
| Assets Under Management (AUM) | N/A |
| Net Asset Value (NAV) | $0.00 |
| Options? | No |
| Total Holdings | N/A |
AMLX Top Holdings
| Symbol | Company | % of Total |
Latest AMLX News From Around the Web
Below are the latest news stories about AMYLYX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AMLX as an investment opportunity.
Is Amylyx (AMLX) Stock a Solid Choice Right Now?Amylyx (AMLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. |
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)CAMBRIDGE, Mass., December 22, 2023--Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP) |
Implied Volatility Surging for Amylyx (AMLX) Stock OptionsInvestors need to pay close attention to Amylyx (AMLX) stock based on the movements in the options market lately. |
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALSCAMBRIDGE, Mass., December 04, 2023--Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS |
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., November 29, 2023--Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
AMLX Price Returns
| 1-mo | -38.19% |
| 3-mo | -88.43% |
| 6-mo | -88.69% |
| 1-year | -93.69% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -87.91% |
| 2023 | -60.16% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |